

**Do Amarin’s commercial plans in the U.S. change as a result of the launch of a second generic version of icosapent ethyl (IPE) from what was described in previous quarterly communications?**

No.

As background, we are aware that, as expected, a second generic version of IPE has become available. Based on Medi-Span, effective June 22, 2021 the wholesale price of the second generic version of IPE is priced at the same price as the first generic product (\$301.86 for 120 count of 1 gram capsules – a 1 month supply). Both launched generics have limited indications (a.k.a. “skinny labels”). They are indicated only for the original indication of VASCEPA: lowering TG in patients with very high TG levels ( $\geq 500$  mg/dL). Patients for this indication represented approximately \$40M of Amarin’s net revenue in the U.S. in 2020.

As of June 22, 2021, we do not yet know the extent to which this second generic has built a bolus of supply prior to launch or the capacity to which they can maintain supply. Both generic companies have expressed in the past that they anticipate having limited supply.

Market dynamics for payors and patients are likely to be unusual relating to these generic products. For example:

- Payors, net of rebates will in many cases find the generic to be more expensive than the branded product
- Patients, particularly those using the co-pay card, will in many cases find the generic to be more expensive than the branded product or the generic to not be covered by insurance
- The generic is only in the U.S.
- We don’t expect these generic companies to support any clinical research or medical education both of which are needed by society for improved patient care

Amarin’s plans are unchanged. We continue to see a large market need for preventative cardiovascular care for which branded VASCEPA is the only labeled product. It is our aim to increase prescriptions of VASCEPA particularly as patients return for ordinary medical care beyond the worries of COVID-19. As we have expressed in the past, we will manage our spending to reflect market dynamics such as COVID-19 and generic supply but we are working to grow branded VASCEPA in the U.S. despite skinny-labeled generic competition. There are, of course, risks and uncertainties to such plan but with a large market need, broad product labeling, continued investment in high volume, high quality, cost-efficient supply, and a very capable commercial team, we believe that continued promotion of branded VASCEPA in this United States is best for patient care and Amarin’s shareholders. Further discussion of our plans has been provided in our quarterly investor updates (e.g. SEC filings, press releases and conference calls).

Dated: June 22, 2021